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Abstract
The care of a patient with amyotrophic lateral sclerosis is complex and involved a wide multidisciplinary 
team. Recent guidelines in the UK have been produced by the National Institute of Health and Care Excel-
lence and this paper looks at the recommendations and implications for practice.
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Introduction
The care of a person with amyotrophic lateral 
sclerosis (ALS, also known as motor neurone disease, 
MND) is complex. The disease is characterised by 
progressive neurodegeneration – primarily of motor 
neurones but affecting the frontal lobes and other 
areas of the brain and nervous system [1]. There is no 
known cause, although 5–10% have a family history 
and for the majority of these people an abnormal 
gene can be found [2]. There is increasing understan-
ding that there is a genetic component with other 
factors causing the development of the disease [2]. 
The prognosis is usually of two to three years from 
diagnosis, although 25% are alive at 5 years and 5% 
at 10 years [1].
The person with ALS faces progressive disability 
— with weakness of arms and legs, speech and swal-
lowing problems and respiratory muscle weakness, 
causing breathlessness and respiratory failure, which 
is the usual cause of death. The family and carers of 
the person with ALS also face multiple losses [3]. The 
aim of care should be to maximise the abilities  the 
person has and to maintain the quality of life. It can be 
argued that palliative care is appropriate from the time 
of diagnosis and certainly the principles of palliative 
care – holistic assessment by a multidisciplinary team 
applied from diagnosis [4].
Within the UK there are different models of care for 
people with ALS. There are specialised MND Centres, 
often supported by the MND Association, but many 
people with ALS do not see specialised services and 
are not well supported through the disease progres-
sion. As a result, the National Institute for Health and 
Care Excellence (NICE) planned a Guideline on the 
management of people with MND. This involved the 
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Organisation of care
The main recommendation for the organisation of 
care is to be for a clinic based MDT. This would usually 
be based in a hospital setting, but could be in the 
community, and would include health and social care 
professionals with expertise in ALS care and working 
closely together. The membership would be: 
•	 Neurologist
•	 Specialist MND nurse
•	 Dietitian
•	 Physiotherapist
•	 Occupational therapist
•	 Respiratory healthcare professional
•	 Speech and language therapist
•	 Palliative care expertise — this may be one of the 
team members. Referral to specialist palliative care 
should be considered if there are complex needs.
Patients would be seen at this Clinic every two to 
three months, but more often if there are increasing 
symptoms or issues and less often if there is slower 
deterioration. The Team would assess, manage and 
review the main areas of care:
•	 Weight, nutritional intake, feeding, swallowing
•	 Muscle problems — weakness, stiffness, cramps
•	 Physical function
•	 Saliva problems — drooling, thick saliva
•	 Speech and communication
•	 Cough effectiveness
•	 Respiratory function
These recommendations are based on several stu-
dies that have shown that not only the quality of life, 
but length of life, are improved with MDT care — one 
study showed one study suggesting the 1 year morta-
lity was decreased by 29.7% [12], another suggesting 
that the median survival was 19 months for the MDT 
group compared to 11 months for standard care [13] 
and a further study showing a survival difference [14].
Other areas of care are considered:
•	 Psychological support
The MDT assessment should include discussion 
of the psychological and emotional impact of 
ALS, and information on possible support systems 
should be provided.
•	 Provision of equipment
The assessment by physiotherapy and occupational 
therapy should be reviewed regularly and include 
consideration of activities of daily living, the home 
environment and the need for technology. Any 
equipment should be provided without delay and 
should be able to be adapted, to cope with the 
person’s deterioration.
formation of a Guideline Development Group, sup-
ported by the technical staff of the National Guideline 
Centre of the Royal College of Physicians. The Group 
considered different aspects of care, looking at the 
evidence of the literature, using the GRADE system, 
and making recommendations for care [5]. If there 
was	insufficient	evidence,	the	recommendations	were	
agreed by consensus discussion. 
There have been previous guidelines for the care 
of people with ALS. In the USA there is a Practice 
Parameter, produced by the American Association of 
Neurology [6] and in Europe the EFNS Guideline on 
ALS [7]. In the UK there had been NICE Guidelines on 
the use of riluzole, the only medication licensed for 
the treatment of ALS, with a small survival advantage 
[8] and on the use of non-invasive ventilation [9]. The 
latter guideline was to be incorporated within this 
new NICE Guideline [10].
This paper focus on the main recommendations, 
and the implications for the care of people with ALS. 
Although this process took place in the UK the evi-
dence was taken widely and the recommendations 
are relevant to other countries, subject to differences 
in health and social care systems.
Recognition and referral
There is awareness that ALS is a rare disease within 
the community and the diagnosis may be delayed. It 
has been recommended that there are clear protocols 
and pathway for referral. Awareness of possible symp-
toms is encouraged and the Royal College of General 
Practitioners and the MND Association have produced 
a	document	on	“Red	flags”	with	suspicion	being	raised	
if there is progressive muscle weakness [11]. It is also 
stressed that information should be provided for the 
patient and family at all stages.
Diagnosis
The diagnosis should be given by a Consultant 
Neurologist with knowledge and expertise in ALS. In 
emergency/urgent situations, such as diagnosis of ALS 
being made at the presentation with acute respiratory 
failure, other specialties may need to tell the diagnosis 
but further discussion should be with an experienced 
neurologist. It is recommended that patients are 
asked about their wishes for information and the 
involvement of their family and information should 
be provided as they wish. A single point of contact 
should be provided, with the ALS Multidisciplinary 
Team (MDT) and one of the Team should see them 
within 4 weeks of the initial appointment to discuss 
the issues that may arise for the patients and family.
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•	 Assessment of cognitive changes
As cognitive change in ALS is more widely under-
stood — with 10–15% of patients having fronto
-temporal dementia and a further 35% showing 
evidence of frontal lobe changes [15] — there is 
a need for discussion about cognition and behaviour 
with patients and their families from diagnosis or if 
there are particular concerns. A formal assessment 
may be necessary. If there is evidence of cognitive 
change, discussions about care may need to be 
carefully tailored to the patient’s needs, conside-
ring their communication abilities, cognition and 
mental capacity to make decisions.
•	 Communication
The needs for face to face, telephone and social 
media communication of a patient should be as-
sessed and the equipment should both low-tech, 
such as a picture board or alphabet board, and 
high-tech, such as computer based technologies. 
•	 Nutrition
There is a need to assess weight, nutrition and 
swallowing from diagnosis. There may be issues 
with the ability to eat and drink – food may need 
special preparation, often a custard consistency is 
easier to swallow, or help may be need in prepara-
tion, aids may be needed to help the person take 
food from the plate to the mouth and advice may 
be needed on posture, positioning and seating 
for mealtimes. There may be the need for advice 
in coping with social situations — as eating is 
often a social and family activity. If swallowing 
problems occur, a careful swallowing assessment 
is necessary and discussion of the placement of 
a gastrostomy should start early and occur regu-
larly. If a gastrostomy is required, this should be 
placed without delay. 
Symptom management
A limited number of symptoms were considered:
•	 Muscle problems
 º Cramps
Cramps may occur in spastic muscles and the 
treatment is recommended;
 º First line — Quinine
 º Second line — Baclofen, tizanidine, dantrolene, 
gabapentin
 º It is important to ensure medication is ap-
propriate, such as can be swallowed and taken 
and the use should be monitored carefully for 
effectiveness and side-effects
 º Physiotherapy
This may help maintain joint movement, prevent 
contractures and reduce stiffness and discomfort. Phy-
siotherapy may be offered as resistance, active assisted 
or passive movements. Families and carers should be 
encouraged to assist in any exercise programme.
•	 Saliva
Careful advice on posture, diet, swallowing and 
oral care is essential. Treatment may be 
A trial of a antimuscarinic — e.g. glycopyrrolate
Injection of Botulinum toxin into salivary glands
If saliva is thick, reduce or stop medication that 
may thicken saliva, advice on diet and postu-
re	and	consider	humidification,	nebulisers	or	
carbocisteine.
•	 Cough augmentation
Cough augmentation techniques should be offered 
if the patient is not able to cough effectively: 
Breath stacking or manual assisted cough may 
be helpful
If there are bulbar changes or breath stacking 
is ineffective, consider:
Assisted breath stacking — using a lung 
volume recruitment bag
Mechanical cough assist machine — par-
ticularly if breath stacking is ineffective or 
during respiratory infection
Respiratory function
There is the need for regular assessment of respi-
ratory	function,	as	the	aim	is	to	find	early	changes,	
before respiratory muscle dysfunction causes respi-
ratory failure. This needs to be carefully explained 
to patients and families and if there is evidence of 
respiratory muscle weakness, causing symptoms such 
as orthopnoea, breathlessness, disturbed sleep or 
morning headache, non-invasive ventilation may need 
to be considered.
NIV may be discussed soon after diagnosis and 
when respiratory monitoring starts. Patients and fa-
milies should be given appropriate information on the 
consideration	of	the	benefits	of	the	improvement	of	
symptoms but also the risks of continued deteriora-
tion and dependency on NIV. Although there is strong 
evidence that NIV will prolong life [16] the underlying 
progression of ALS will not be altered. 
NIV should be offered if there are symptoms and 
evidence of respiratory muscle weakness and may 
be started initially by acclimatisation in the day and 
slowly increasing the use at night. There is a need to 
undertake a risk assessment of how the patient and 
their family will cope with the NIV interface, and the 
risks of ventilator or power failure. This will include 
discussion about their wishes if there are further pro-
blems, such as infection or increasing dependency or 
symptoms. Medication to cope with breathlessness 
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and distress — morphine sulphate, midazolam, and 
an antimuscarinic, such as glycopyrronium bromide 
or hyoscine hydrobromide — may be provided, so 
that they are readily available if there is a sudden 
deterioration. 
If a patient has frontotemporal dementia or se-
vere bulbar problems, with severe drooling of saliva, 
NIV may not be easy to cope with. The use of NIV 
may need to be carefully assessed and may not be 
appropriate. If there are severe symptoms a trial of 
NIV could be considered.
Some patients on NIV will become dependent 
and even approach using the ventilator support for 
24 hours a day. They may ask to stop the NIV and if 
the patient is able to make this decision autonomously 
it is ethical for this treatment to be withdrawn. Ho-
wever, a plan to withdraw is essential, as medication 
may be needed to ensure that they do not become 
distressed. Extra support is also needed for family and 
all the professionals in the team [17].
End of life care
There are clear recommendations that all profes-
sionals should be prepared to discuss end of life care 
whenever the patient and family ask and to provide 
advice on advance care planning, so that the patient’s 
wishes are known if they lose capacity to make deci-
sions later by themselves. These wishes may include 
their wish of place of care, place of death and what 
they would like to happen if they deteriorate suddenly 
or develop a severe infection or another illness or 
complication. Specialist palliative care services may 
become involved if they are not already seeing the 
patient and family.
As the end of life approaches extra help should 
be provided to allow the family and carers to spend 
more time with the patient and have some of the re-
sponsibility for care to be lessened. Extra equipment 
and care should be provided if they are not already 
present, such as communication aids, specialised 
beds, commode or a hoist. Bereavement care should 
be available for families after death.
Conclusion
These guidelines allow health and social care pro-
fessionals to develop improved care for all people with 
ALS, using an evidence based approach. The challenge 
is now to ensure that the recommendations are imple-
mented and patients and their families can experience 
the improvement in the care they receive.
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